Rosetta Genomics (NASDAQ: ROSG) and Senomyx (NASDAQ:SNMX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
This is a breakdown of current ratings for Rosetta Genomics and Senomyx, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Rosetta Genomics and Senomyx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
7.5% of Rosetta Genomics shares are held by institutional investors. Comparatively, 26.8% of Senomyx shares are held by institutional investors. 12.4% of Senomyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Rosetta Genomics has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Senomyx has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.
Earnings and Valuation
This table compares Rosetta Genomics and Senomyx’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Rosetta Genomics||$9.23 million||0.37||-$16.23 million||N/A||N/A|
|Senomyx||$23.04 million||2.90||-$10.68 million||($0.26)||-5.38|
Senomyx has higher revenue and earnings than Rosetta Genomics.
Senomyx beats Rosetta Genomics on 7 of the 10 factors compared between the two stocks.
About Rosetta Genomics
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.
Senomyx, Inc. is focused on using taste receptor technologies to discover, develop and commercialize flavor ingredients for the packaged food, beverage and ingredient supply industries. The Company operates through development and commercialization of flavor ingredients segment. It is engaged in the discovery, development and/or commercialization of flavor ingredients through over five programs. The Sweet Taste Program is focused on developing flavor ingredients or discovering natural sweeteners. The Savory Flavor Program is focused at flavor ingredients to be used in product categories, such as ready meals, sauces, soups and snack foods. The Bitter Blocker Program is focused on flavor ingredients used in products that contain bitter tastants. The Cooling Taste Program is focused at flavor ingredients used in products that consist of cooling agents. The salt taste modifier program is focused on reduction of the level of salt contained in packaged food and beverage products.
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.